| Dr Edward Mark Kramer, MD | |
|
3055 W Orange Ave, #207, Anaheim, CA 92804-3159 | |
| (714) 229-8246 | |
| (714) 229-9362 |
| Full Name | Dr Edward Mark Kramer |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 38 Years |
| Location | 3055 W Orange Ave, Anaheim, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548302243 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aesthetic Dermatology And Laser Center Medical Group Inc | 3779674601 | 2 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.
BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it plans to initiate a Phase 3 pivotal trial of lead product candidate, Plinabulin, in patients with non-small cell lung cancer (NSCLC) in the first quarter of 2015.
Health-conscious people know that high levels of total cholesterol and LDL cholesterol (the so-called "bad" cholesterol) can increase the risk of heart attacks. Now scientists are reporting that another form of cholesterol called oxycholesterol - virtually unknown to the public - may be the most serious cardiovascular health threat of all. Scientists from China presented one of the first studies on the cholesterol-boosting effects of oxycholesterol here today at the 238th National Meeting of the American Chemical Society. The researchers hope their findings raise public awareness about oxycholesterol, including foods with the highest levels of the substance and other foods that can combat oxycholesterol's effects.
Just one in three women gives birth after a single IVF attempt, but the cumulative chance of a live birth increases with each cycle - where women are offered three cycles nearly two thirds go on to have babies, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg in Sweden.
› Verified 1 days ago
| Entity Name | Aesthetic Dermatology & Laser Center Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255473815 PECOS PAC ID: 3779674601 Enrollment ID: O20070807000764 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.
BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it plans to initiate a Phase 3 pivotal trial of lead product candidate, Plinabulin, in patients with non-small cell lung cancer (NSCLC) in the first quarter of 2015.
Health-conscious people know that high levels of total cholesterol and LDL cholesterol (the so-called "bad" cholesterol) can increase the risk of heart attacks. Now scientists are reporting that another form of cholesterol called oxycholesterol - virtually unknown to the public - may be the most serious cardiovascular health threat of all. Scientists from China presented one of the first studies on the cholesterol-boosting effects of oxycholesterol here today at the 238th National Meeting of the American Chemical Society. The researchers hope their findings raise public awareness about oxycholesterol, including foods with the highest levels of the substance and other foods that can combat oxycholesterol's effects.
Just one in three women gives birth after a single IVF attempt, but the cumulative chance of a live birth increases with each cycle - where women are offered three cycles nearly two thirds go on to have babies, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg in Sweden.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Edward Mark Kramer, MD 3055 W Orange Ave, #207, Anaheim, CA 92804-3159 Ph: (714) 229-8246 | Dr Edward Mark Kramer, MD 3055 W Orange Ave, #207, Anaheim, CA 92804-3159 Ph: (714) 229-8246 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.
BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it plans to initiate a Phase 3 pivotal trial of lead product candidate, Plinabulin, in patients with non-small cell lung cancer (NSCLC) in the first quarter of 2015.
Health-conscious people know that high levels of total cholesterol and LDL cholesterol (the so-called "bad" cholesterol) can increase the risk of heart attacks. Now scientists are reporting that another form of cholesterol called oxycholesterol - virtually unknown to the public - may be the most serious cardiovascular health threat of all. Scientists from China presented one of the first studies on the cholesterol-boosting effects of oxycholesterol here today at the 238th National Meeting of the American Chemical Society. The researchers hope their findings raise public awareness about oxycholesterol, including foods with the highest levels of the substance and other foods that can combat oxycholesterol's effects.
Just one in three women gives birth after a single IVF attempt, but the cumulative chance of a live birth increases with each cycle - where women are offered three cycles nearly two thirds go on to have babies, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg in Sweden.
› Verified 1 days ago
Marina A. Ball, MD Dermatology Medicare: Medicare Enrolled Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 | |
Silvia Song, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5475 E La Palma Ave, Anaheim, CA 92807 Phone: 888-988-2800 | |
Dr. Sam A. Samimi, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 1165 N Euclid St, Anaheim, CA 92801 Phone: 714-991-9990 Fax: 714-991-9496 | |
Robert A. Langer, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 | |
Hundi Mohan Kamath, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 | |
Arline M. Tsuchiya, MD Dermatology Medicare: Medicare Enrolled Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 | |
Brian Norman Streams, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 |